Entropy Neurodynamics sets up US Phase 2 head-to-head trial of TRP-8803 against leading antidepressant

Entropy Neurodynamics Ltd (ASX:ENP, OTC:TYPTF) has secured a pre-clinical trial agreement with the University of California, San Francisco (UCSF) for a proposed US Phase 2 study comparing its precision-controlled psychedelic therapy TRP-8803 directly with widely prescribed antidepressant escitalopram.